Skip to content

Sarepta upped to buy by Leerink, target $47

March 3, 2017

Leerink Partners upgraded Sarepta Therapeutics (NASDAQ: SRPT) from Market Perform to Outperform with a price target of $47.00 (from $32.00).

Analyst Joe Schwartz comments “We are upgrading SRPT to Outperform and raising our PT to $47 from $27 now that the stock appears to have fully consolidated and reflects reasonable expectations for the Exondys launch, following management’s new revenue guidance ($13-15M in 1Q and over $80M in FY17) which looks highly conservative to us.”


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: